Roshan Katekar

Dr. Roshan Katekar


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
RGRicha Garg
Richa Garg
SKSanjana Kumariya
Sanjana Kumariya
RKRoshan Katekar
Roshan Katekar
SVSaurabh Verma
Saurabh Verma
UGUmesh K. Goand
Umesh K. Goand
JGJiaur R. Gayen
Jiaur R. Gayen

27 November 2019 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
RKRoshan Katekar
Roshan Katekar
GTGaneshkumar Thombre
Ganeshkumar Thombre
MRMohammed Riyazuddin
Mohammed Riyazuddin
AHAthar Husain
Athar Husain
HRHiral Rani
Hiral Rani
JGJiaur R. Gayen
Jiaur R. Gayen
Trans-Resveratrol (T-RES) is compound with wide therapeutic applications shows low bioavailability and distribution across blood-brain barrier. The purpose of our study was to develop T-RES loaded mixed micelle (T-RES-MM) for its enhanced systemic availability and targeting to the brain. T-RES-MMs were formulated using Pluronic F-127 (PF-127) and d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) by using film hydration process. Formulations were characterized for size of particles, zeta potential, drug efficiency of entrapment, drug loading, and haemolytic study. Further in vivo pharmacokinetic and brain distribution study carried out in Sprague Dawley rats. The nano ranged size for drug loaded mixed micelles was 21.55 ± 2.15 nm for optimized formulation with PF-127:TPGS (4:1). Formulation with maximum drug loading and entrapment efficiency of 8.4 ± 0.37% and 94.37 ± 1.01% respectively were further used for in vivo study. Percent haemolysis by micelles at all concentrations indicates the biocompatibility and safety for administration by i.v. route. The AUC0-t for T-RES-MM was 460.98 ± 158.99 hr*ng/mL while for T-RES it was 276.27 ± 174.05 hr*ng/mL. Drug targeting index suggests successful targeting of T-RES to the brain. Overall findings conclude in, prepared T-RES-MM exhibit superiority of formulation as compared to T-RES solution.

1 December 2020 in Heliyon
Verified
Journal Article
Open access
PSPragati Singh
Pragati Singh
MRMohammad Irshad Reza
Mohammad Irshad Reza
SASyed Anees Ahmed
Syed Anees Ahmed
RGRicha Garg
Richa Garg
AHAthar Husain
Athar Husain
JGJiaur R. Gayen
Jiaur R. Gayen
Hepatic steatosis in women confronting menopause is the manifestation of substantial fructose consumption and forms a positive feedback loop to develop endoplasmic reticulum (ER) stress. Previously pancreastatin inhibitor peptide-8 (PSTi8) and Metformin (Met) combination effectively ameliorated hepatic lipid accumulation in high fructose diet (HFrD) fed diabetic mice models at reduced doses. Moreover, SIRT-1 plays a crucial role in the regulation of SREBP-1c. Hence we hypothesized that Met and PSTi8 in combination (at therapeutic lower doses) could mitigate hepatic steatosis linked ER stress by activating SIRT-1 and precluding SREBP-1c in HFrD fed 4-Vinylcyclohexenediepoxide (HVCD) induced perimenopausal rats. HVCD rats were fed HFrD for 12 weeks, accompanied by 14 days of treatment with Met, PSTi8, and combination. We confirmed model establishment by estrus cycle study, estradiol level, and intraperitoneal glucose tolerance test. Plasma lipid profile and liver function were determined. Also, mRNA and protein expressions were examined. Moreover, distribution of SIRT-1 and SREBP-1c was detected in HepG2 cells by immunofluorescence staining. HVCD group displayed augmented insulin resistance (IR), lipogenesis, and ER stress in the liver. Combination therapy improved the estrus cyclicity, estradiol, and lipid profile of HVCD rats. Met and PSTi8 combination reduced hepatic SREBP-1c and triggered SIRT-1 expression in high fructose-induced insulin-resistant HepG2 cells; consequently, combination therapy attenuated ER stress. Succinctly, present research promotes impetus concerning the remedial impact of Met with PSTi8 at lower therapeutic doses to ameliorate hepatic IR, steatosis, and associated ER stress by revamping the SIRT-1/SREBP-1c axis in perimenopausal rats.

1 January 2019 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
Riyazuddin MohammedRiyazuddin Mohammed
Riyazuddin Mohammed
GVGuru Raghavendra Valicherla
Guru Raghavendra Valicherla
AHAthar Husain
Athar Husain
Mohd Kamil HussainMohd Kamil Hussain
Mohd Kamil Hussain
MSMinakshi Shukla
Minakshi Shukla
JGJiaur R. Gayen
Jiaur R. Gayen

6 May 2022 in Journal of Liposome Research
Verified
Journal Article
Closed access
RKRoshan Katekar
Roshan Katekar
SSSumati Sen
Sumati Sen
MRMohammed Riyazuddin
Mohammed Riyazuddin
AHAthar Husain
Athar Husain
RGRicha Garg
Richa Garg
JGJiaur R. Gayen
Jiaur R. Gayen
Abiraterone acetate (ABRTA) is clinically beneficial in management of metastatic castration-resistant prostate cancer (PC-3). With highlighted low solubility and permeability, orally hampered treatment of ABRTA necessitate high dose to achieve therapeutic efficacy. To triumph these challenges, we aimed to develop intestinal lymphatic transport facilitating lipid-based delivery to enhance bioavailability. ABRTA-containing self-nano emulsified drug delivery (ABRTA-SNEDDS) was statistically optimized by D-optimal design using design expert. Optimized formulation was characterized for particle size, thermodynamic stability, in vitro release, in vivo bioavailability, intestinal lymphatic transport, in vitro cytotoxic effect, anti-metastatic activity, and apoptosis study. Moreover, hemolysis and histopathology studies have been performed to assess pre-clinical safety. Nano-sized particles and successful saturated drug loading were obtained for optimized formulation. In vitro release upto 98.61 ± 3.20% reveal effective release of formulation at intestinal pH 6.8. ABRTA-SNEDDS formulation shows enhanced in vivo exposure of Abiraterone (2.5-fold) than ABRTA suspension in Sprague–Dawley rats. In vitro efficacy in PC-3 cell line indicates 3.69-fold higher therapeutic potential of nano drug delivery system. Hemolysis and histopathology study indicates no significant toxicities to red blood cells and tissues, respectively. Apparently, an opportunistic strategy to increasing bioavailability of ABRTA via intestinal lymphatic transport will create a viable platform in rapidly evolving chemotherapy. Enhanced translational utility of delivery was also supported through in vitro therapeutic efficacy and safety assessments.

1 August 2021 in Life Sciences
Verified
Journal Article
Closed access
PSPragati Singh
Pragati Singh
MRMohammad Irshad Reza
Mohammad Irshad Reza
SASyed Anees Ahmed
Syed Anees Ahmed
AHAthar Husain
Athar Husain
RKRoshan Katekar
Roshan Katekar
JGJiaur R. Gayen
Jiaur R. Gayen